据报告,在ELPIS I试验中,Lomecel-BTM疗法的5年存活率为100%,没有心脏移植。 5-year survival rate of 100% without heart transplants reported for Lomecel-B™ therapy in ELPIS I trial.

Longeveron Inc.在CHSS第51届年度会议上分享了处理Lomecel-BTM的有希望的长期生存数据。 Longeveron Inc. shared promising long-term survival data for its treatment Lomecel-B™ at the CHSS 51st Annual Meeting. 在ELPIS I试验中,在第二阶段格伦外科手术后接受治疗的病人,在没有心脏移植的情况下,存活率达到100%的五年,大大高于单一气管重建试验的83%。 In the ELPIS I trial, patients who received the therapy after stage 2 Glenn surgery achieved a 100% five-year survival rate without heart transplants, significantly higher than the 83% rate from the Single Ventricle Reconstruction Trial. 该公司目前正在实施ELPIS II,以进一步评估Hypollatic Left Heart综合症的Lomecel-BTM。 The company is now conducting ELPIS II to further assess Lomecel-B™ for Hypoplastic Left Heart Syndrome.